
## Elizabeth A Morgan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/421679/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Journal of Clinical Oncology, 2017, 35, 1598-1605.	1.6	339
2	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood, 2016, 128, 195-203.	1.4	259
3	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	16.8	227
4	Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discovery, 2016, 6, 368-381.	9.4	215
5	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discovery, 2017, 7, 156-164.	9.4	164
6	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood, 2016, 128, 1093-1100.	1.4	126
7	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports, 2015, 12, 622-635.	6.4	123
8	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. Journal of Clinical Oncology, 2020, 38, 2380-2389.	1.6	110
9	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. American Journal of Surgical Pathology, 2018, 42, 293-305.	3.7	80
10	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nature Communications, 2018, 9, 2024.	12.8	80
11	Cutaneous Radiation-Associated Angiosarcoma of the Breast: Poor Prognosis in a Rare Secondary Malignancy. Annals of Surgical Oncology, 2012, 19, 3801-3808.	1.5	76
12	Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell, 2017, 21, 547-555.e8.	11.1	71
13	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. British Journal of Haematology, 2015, 169, 851-858.	2.5	63
14	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. Journal of Investigative Dermatology, 2018, 138, 2365-2376.	0.7	59
15	Antagonizing Integrin β3 Increases Immunosuppression in Cancer. Cancer Research, 2016, 76, 3484-3495.	0.9	58
16	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Advances, 2019, 3, 2199-2204.	5.2	52
17	lgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	4.1	45
18	Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas. Blood, 2019, 134, 1430-1440.	1.4	45

ELIZABETH A MORGAN

#	Article	IF	CITATIONS
19	Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances, 2019, 3, 1540-1545.	5.2	44
20	Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discovery, 2022, 12, 522-541.	9.4	44
21	Intergenerational epigenetic inheritance of cancer susceptibility in mammals. ELife, 2019, 8, .	6.0	43
22	Detection of activating <i>MAP2K1</i> mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leukemia and Lymphoma, 2017, 58, 233-236.	1.3	39
23	Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. JCI Insight, 2021, 6, .	5.0	39
24	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. Cancer Discovery, 2019, 9, 944-961.	9.4	36
25	Immunohistochemical Detection of Hairy Cell Leukemia in Paraffin Sections Using a Highly Effective CD103 Rabbit Monoclonal Antibody. American Journal of Clinical Pathology, 2013, 139, 220-230.	0.7	30
26	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. Blood Advances, 2021, 5, 649-661.	5.2	26
27	Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: An Underrecognized Aggressive Lymphoma. Advances in Hematology, 2012, 2012, 1-6.	1.0	25
28	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Advances, 2021, 5, 2481-2489.	5.2	25
29	PAX8 and PAX5 are differentially expressed in Bâ€cell and Tâ€cell lymphomas. Histopathology, 2013, 62, 406-413.	2.9	21
30	Clinical utility of targeted next-generation sequencing–based screening of peripheral blood in the evaluation of cytopenias. Blood, 2019, 134, 2222-2225.	1.4	21
31	Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities. Blood, 2015, 126, 497-497.	1.4	21
32	Lymphoma and Pathology in Sub-Saharan Africa. Clinics in Laboratory Medicine, 2018, 38, 91-100.	1.4	20
33	Infectious Granulomatous Dermatitis Associated With Rothia mucilaginosa Bacteremia: A Case Report. American Journal of Dermatopathology, 2010, 32, 175-179.	0.6	18
34	NK-Cell Enteropathy and Similar Indolent Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2019, 151, 75-85.	0.7	18
35	Coreâ€binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (l―CBF) Tj	ETQq1 1 2.8	0.784314 rg <sup>81</sup> 17
36	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. Blood, 2020, 136, 3051-3055.	1.4	15

3

#	Article	IF	CITATIONS
37	Myeloid neoplasm demonstrating a <i>STAT5B-RARA</i> rearrangement and genetic alterations associated with all- <i>trans</i> retinoic acid resistance identified by a custom next-generation sequencing assay. Journal of Physical Education and Sports Management, 2015, 1, a000307.	1.2	13
38	Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Advances, 2017, 1, 1786-1789.	5.2	13
39	Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. Modern Pathology, 2020, 33, 1135-1145.	5.5	12
40	Imaging of IgG4-Related Disease in the Head and Neck: A Systematic Review, Case Series, and Pathophysiology Update. Journal of Neuroradiology, 2021, 48, 369-378.	1.1	11
41	Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues. Histopathology, 2017, 71, 112-124.	2.9	10
42	Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. Journal of Cutaneous Pathology, 2019, 46, 823-829.	1.3	10
43	Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Advances, 2020, 4, 1006-1011.	5.2	10
44	Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Human Pathology, 2019, 93, 54-64.	2.0	8
45	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Advances, 2020, 4, 925-929.	5.2	8
46	Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. Blood Advances, 2016, 1, 84-92.	5.2	6
47	LIM domain only 2 (LMO2) expression distinguishes Tâ€lymphoblastic leukemia/lymphoma from indolent Tâ€lymphoblastic proliferations. Histopathology, 2020, 77, 984-988.	2.9	6
48	Coreâ€binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology, 2021, 43, e19-e25.	1.3	6
49	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. Blood, 2012, 120, 1545-1545.	1.4	6
50	Case report and literature review: cardiac tamponade as a complication of pericardial extramedullary hematopoiesis. Cardiovascular Pathology, 2016, 25, 371-374.	1.6	5
51	Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). American Journal of Clinical Pathology, 2019, 152, 302-321.	0.7	5
52	Myelodysplastic syndromes with no somatic mutations detected by nextâ€generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. American Journal of Hematology, 2021, 96, E420-E423.	4.1	5
53	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Advances, 2020, 4, 5089-5092.	5.2	5
54	Many faces of the same myeloid neoplasm: a case of leukaemia cutis with mixed histiocytic and Langerhans cell differentiation. Journal of Clinical Pathology, 2019, 72, 93-96.	2.0	4

#	Article	IF	CITATIONS
55	Developmental Ontogeny of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Revealed By Recurrent High Burden Clonal Hematopoiesis, Including in "Skin-Only" Disease. Blood, 2018, 132, 2755-2755.	1.4	4
56	<scp>Epsteinâ€Barr</scp> virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018. International Journal of Cancer, 2022, 150, 753-760.	5.1	4
57	A novel in vivo model for studying conditional dual loss of BLIMPâ€1 and p53 in Bâ€cells, leading to tumor transformation. American Journal of Hematology, 2017, 92, E138-E145.	4.1	3
58	Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering. Blood, 2016, 128, 741-741.	1.4	3
59	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. Blood, 2016, 128, 986-986.	1.4	3
60	Harmonization of the Essentials: Matching Diagnostics to Treatments for Global Oncology. JCO Global Oncology, 2020, 6, 1352-1356.	1.8	2
61	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. Blood, 2015, 126, 3252-3252.	1.4	2
62	Physical Interaction Between Mutant Calreticulin and the Thrombopoietin Receptor Is Required for Hematopoietic Transformation. Blood, 2015, 126, LBA-4-LBA-4.	1.4	2
63	Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature. Journal of Global Oncology, 2019, 5, 1-6.	0.5	1
64	Concomitant classic Hodgkin lymphoma and schistosomiasis. American Journal of Hematology, 2019, 94, 840-841.	4.1	1
65	Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo Models of Cohesin-Mutant Myeloid Diseases. Blood, 2019, 134, 560-560.	1.4	1
66	Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis. Blood, 2020, 136, 13-14.	1.4	1
67	T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development. Blood, 2016, 128, 3015-3015.	1.4	1
68	Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities. Blood, 2018, 132, 1819-1819.	1.4	1
69	Incidence and Clinical Features of Extramedullary Multiple Myeloma in Patients Who Underwent Stem Cell Transplantation. Blood, 2014, 124, 5746-5746.	1.4	0
70	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. Blood, 2015, 126, 2655-2655.	1.4	0
71	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. Blood, 2015, 126, 4001-4001.	1.4	0
72	Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma. Blood, 2015, 126, 3925-3925.	1.4	0

Elizabeth A Morgan

#	Article	IF	CITATIONS
73	Systematic STAT3 Mutation Testing Identifies Patients with Unsuspected T-Cell Large Granular Lymphocytic Leukemia. Blood, 2016, 128, 919-919.	1.4	0
74	Dual Conditional Loss of BLIMP-1 and p53 in B-Cells Drives B-Cell Lymphomagenesis. Blood, 2016, 128, 4169-4169.	1.4	0
75	Flow cytometry minimal residual disease assessment in peripheral blood of adult acute lymphoblastic leukemia patients Journal of Clinical Oncology, 2017, 35, e18517-e18517.	1.6	0
76	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. Blood, 2018, 132, 817-817.	1.4	0
77	Clinical Utility of Routine Targeted Next-Generation Sequencing of Peripheral Blood in the Evaluation of Patients with Cytopenias. Blood, 2018, 132, 3090-3090.	1.4	0
78	Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas. Blood, 2018, 132, 339-339.	1.4	0